Information Provided By: 
Fly News Breaks for January 23, 2020
AIMT
Jan 23, 2020 | 09:03 EDT
Roth Capital analyst Zegbeh Jallah raised her price target for Aimmune to $50 from $45 as the analyst remains bullish on Palforzia's launch outlook. Jallah notes that FDA's decision on Palforizia is still expected by the end of January, and EMA's approval of Palforzia is expected during the second half of 2020. The analyst has a Buy rating on the shares.
News For AIMT From the Last 2 Days
There are no results for your query AIMT
